-
14-05-2019, 04:49 PM
#361
QVC has worked out quite well for them in Japan (127 million) already putting Advangen (the subsidiary company owned by Cellmid) into profit.
If QVC and Fukangren both start in China(1.4 Billion) plus the USA (329 million) and the EU (511 million) have a similar takeup to Japan then a Market Cap of $16.8 million for ASX:CDY will seem ludicrous.
There is no debt to speak of and they have 4.8 million in the bank
Last edited by Minerbarejet; 15-05-2019 at 08:11 AM.
-
15-05-2019, 08:11 AM
#362
Of course this is not just about Evolis.
Some very interesting other news regarding Midkine
https://www.ncbi.nlm.nih.gov/pubmed/30993586
-
16-05-2019, 06:33 AM
#363
Member
And from the CEO herself here she is in New York one day ago talking to Proactive Investors USA about the company and its progress.She is expecting profitability to start kicking in for most months of FY2020.About 4.40 into the interview.
https://www.youtube.com/watch?featur...pI&app=desktop
Last edited by Tsuba; 16-05-2019 at 06:38 AM.
-
17-05-2019, 12:09 PM
#364
And on top of all this PEB has had a great publication in the European Urology Journal with outstanding and "compelling" results of its cxbladder test.
PEB utilises Midkine in the cxBladder test and pay royalties to CDY on tests used.
-
17-05-2019, 10:36 PM
#365
Member
Originally Posted by Tsuba
And from the CEO herself here she is in New York one day ago talking to Proactive Investors USA about the company and its progress.She is expecting profitability to start kicking in for most months of FY2020.About 4.40 into the interview.
https://www.youtube.com/watch?featur...pI&app=desktop
Thanks for the link Tsuba, sounds very positive. I expect the profitability will start to attract new investors. Will be interesting to see how the proposed split of the two businesses works out.
-
19-05-2019, 03:58 PM
#366
Member
No problem Elles this may also interest you. Yesterday I spoke to a Chinese lady from Beijing. She works for a cosmetics company in marketing. She was telling me that the 1990’s generation are suffering hair loss due to the extreme stress of work amongst other things. To quote her the hair loss market in China is HUGE.
I did a marketing exercise with her regarding Evolis, Advangen, FGF5 and Fukangren. When she gets back she will research our company.
-
20-05-2019, 04:47 PM
#367
-
24-05-2019, 02:47 PM
#368
Seems they have had a bit of a cleanout of shareholders with unmarketable parcels.
Should streamline the share register a bit with 29% less paperwork.
The shares were cancelled so there are nearly 500,000 less issued now.
-
27-05-2019, 06:43 PM
#369
It would appear that a split or some shakeup may be imminent.
A job application for a CEO for company called Advangen Australia has had 74 applications and has now closed.
That level of interest is great.
The market continues to not like uncertainty, as usual.
-
28-05-2019, 01:03 PM
#370
Certainly given the market a shake this morning.
Up 3 on the back of a new CEO for the Lyramid (Midkine) section and an outstanding update to the way ahead in a newsletter.
https://www.asx.com.au/asxpdf/201905...ygpndcmfgb.pdf
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks